Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases

Lancet Oncol. 2018 Jun;19(6):e327. doi: 10.1016/S1470-2045(18)30252-3. Epub 2018 Jun 1.

Authors

Henrik Jespersen¹, Sara Bjursten¹, Lars Ny¹, Max Levin²

Affiliations

¹ Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.
² Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden. Electronic address: max.levin@wlab.gu.se.

PMID: 29893264
DOI: 10.1016/S1470-2045(18)30252-3

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects*
Antineoplastic Agents, Immunological / adverse effects*
Bone Neoplasms / diagnostic imaging
Bone Neoplasms / secondary*
Diagnosis, Differential
Female
Glucocorticoids / therapeutic use
Humans
Melanoma / diagnostic imaging
Melanoma / drug therapy*
Melanoma / secondary
Middle Aged
Positron Emission Tomography Computed Tomography
Predictive Value of Tests
Prednisone / therapeutic use
Sarcoidosis / chemically induced*
Sarcoidosis / diagnostic imaging
Sarcoidosis / drug therapy
Skin Neoplasms / diagnostic imaging
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology
Treatment Outcome
Whole Body Imaging / methods

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Glucocorticoids
pembrolizumab
Prednisone